 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 GLOBE NEWSWIRE -- Nkarta, Inc. Nasdaq: NKTX, a clinical-stage biopharmaceutical company developing engineered natural killer NK cell therapies to treat cancer, today announced a preclinical update on NKX019, its investigational allogeneic cancer immunotherapy that uses donor-derived natural killer NK cells engineered with a membrane-bound form of IL15 and a chimeric antigen receptor CAR targeting the CD19 antigen. 